.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ATTEST-2 randomized trial compared tenecteplase 0.25 mg/kg with standard-dose alteplase in adults eligible for intravenous thrombolysis within 4.5 hours of acute ischemic stroke onset. The study used a pragmatic multicentre design with masked endpoint assessment and focused on the distribution of modified Rankin Scale scores at 90 days. The findings supported tenecteplase as at least a non-inferior alternative to alteplase, adding to the growing evidence that a single-bolus fibrinolytic can perform comparably to an infusion-based regimen. This matters operationally because streamlined administration can potentially reduce treatment delays, especially in stroke systems that need to move rapidly from imaging to reperfusion. For HCPs, tenecteplase should be considered within established eligibility and dosing frameworks rather than as a universal replacement regardless of setting. The study contributes to an evolving body of evidence supporting tenecteplase across different stroke populations. Together with other randomized trials, it strengthens the scientific basis for revisiting thrombolysis protocols while keeping patient selection and haemorrhagic risk assessment central.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ATTEST-2 randomized trial compared tenecteplase 0.25 mg/kg with standard-dose alteplase in adults eligible for intravenous thrombolysis within 4.5 hours of acute ischemic stroke onset. The study used a pragmatic multicentre design with masked endpoint assessment and focused on the distribution of modified Rankin Scale scores at 90 days. The findings supported tenecteplase as at least a non-inferior alternative to alteplase, adding to the growing evidence that a single-bolus fibrinolytic can perform comparably to an infusion-based regimen. This matters operationally because streamlined administration can potentially reduce treatment delays, especially in stroke systems that need to move rapidly from imaging to reperfusion. For HCPs, tenecteplase should be considered within established eligibility and dosing frameworks rather than as a universal replacement regardless of setting. The study contributes to an evolving body of evidence supporting tenecteplase across different stroke populations. Together with other randomized trials, it strengthens the scientific basis for revisiting thrombolysis protocols while keeping patient selection and haemorrhagic risk assessment central.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
